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Edited by Veli-Pekka LehtoAbstract Adiponectin can protect vessels from injury by
promoting the activity of endothelial nitric oxide synthase
(eNOS) with increased nitric oxide production. Recently, it
was demonstrated that eNOS activity is highly regulated by heat
shock protein 90 (HSP90). We tested the hypothesis that
adiponectin can prevent endothelial cell injury produced by
angiotensin II through promotion of the association between
eNOS and HSP90. Cultured human umbilical vein endothelial
cells (HUVECs) were treated with angiotensin II (2 lM) to
induce apoptosis. In the presence of globular adiponectin,
apoptosis was inhibited in a dose–response manner. Angiotensin
II-induced apoptosis was also inhibited by treatment with an NO
donor and by combined treatment with both angiotensin II type 1
and type 2 receptor blockers. Western blotting and immunopre-
cipitation of the lysates from the treated cells showed that
globular adiponectin could restore the association between
eNOS and HSP90 and enhance the phosphorylation of eNOS.
In conclusion, angiotensin II-induced human endothelial cell
apoptosis can be prevented by adiponectin through promotion
and stabilization of the association between eNOS and HSP90.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Endothelial cell1. Introduction
Adiponectin is abundantly expressed in adipose tissue. It
has been reported that adiponectin is reduced in patients
with increased insulin resistance, such as obesity, type 2 di-
abetes, coronary artery disease and hypertension [1–3]. In
addition to the metabolic eﬀects, adiponectin was found to
protect vessels from damage through various mechanisms. It
was demonstrated that adiponectin could inhibit adhesion of
monocyte to endothelial cells [4,5] and transformation of
macrophage to foam cell [6]. In one in vivo study, adipo-
nectin-deﬁcient mice exhibited excessive vascular remodeling
to acute injury [7]. In another mouse atherosclerosis model,* Corresponding author. Fax: +886-2-23935346.
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doi:10.1016/j.febslet.2004.08.012enhanced adiponectin expression could reduce atherosclerotic
changes [8]. Recently, it was demonstrated that adiponectin
can directly stimulate the production of nitric oxide (NO), an
important mediator that regulates vascular tone and func-
tion, through AMPK–PI3–kinase–Akt–eNOS-signaling axis
[9,10].
It is well known that impairment in endothelial nitric oxide
synthase (eNOS) activity plays an important role in the path-
ogenesis of endothelial cell dysfunction. Recent studies indi-
cate that eNOS is highly regulated by post-translational
modiﬁcations, such as Akt-induced phosphorylation [11,12]
and interaction with several regulatory proteins, such as heat
shock protein 90 (HSP90) [13–15]. Binding of HSP90 ensures
recruitment of activated Akt to eNOSnHSP90 complex and
phosphorylation of eNOS [13]. HSP90 also plays an important
role in the balance between NO and superoxide. HSP90 in-
hibitors, such as radicicol and geldanamycin, can increase
eNOS-dependent superoxide anion production by uncoupling
eNOS [16,17]. These observations suggest that the associa-
tion of HSP90 with eNOS is critical in eNOS-associated NO
production.
Endothelial cell injury is considered a critical event in the
pathogenesis of atherosclerosis, plaque erosion, and thrombus
formation [18]. In atherosclerosis lesions, the turnover rates of
endothelial cells are accelerated and local endothelial cell ap-
optosis is implicated in this process [19]. Endothelial cell injury
can be induced by high glucose, angiotensin II and oxidized
low-density lipoprotein [20–23]. One recent study has shown
that high molecular weight adiponectin can prevent human
umbilical vein endothelial cells (HUVECs) from apoptosis
through AMPK signaling pathway [24].
In the present study, we tested the hypothesis that adipo-
nectin can prevent endothelial cell apoptosis induced by an-
giotensin II through promotion of the association between
eNOS and HSP90.2. Materials and methods
2.1. Cell culture and cell treatment
Human umbilical vein endothelial cells were cultured as previously
described [25]. Cells were seeded at a density of 1 105 per 75 cm2 ﬂask
in medium 199 (Gibco), supplemented with 20 mmol/l HEPES, 100 lg/
ml endothelial cell growth substance (Collaborative Research Inc), andblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀects of adiponectin on angiotensin II-induced apoptosis.
HUVECs were exposed to angiotensin II (2 lM) for 18 h with or
without pre-treatment with various concentrations of globular adipo-
nectin (2, 5 or 10 lg/ml) for 1 h. (A) Globular adiponectin prevents
angiotensin II-induced apoptosis in a dose–response manner
(*P < 0:05 compared with control and previous condition; **P < 0:05
compared with control). (B) Lysates from the treated HUVECs were
immunoblotted with polyclonal antibody against caspase-3. Data are
presented as meansS.E.M. (n ¼ 3).
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with a gas mixture of 5% CO2–95% air. Subcultures were performed
with trypsin-EDTA. All media were supplemented with 5 U/ml hep-
arin, 100 IU/ml penicillin, and 0.1 mg/ml streptomycin. Medium was
refreshed every third day. Endothelial cells of the third to ﬁfth passages
in actively growing condition were used for experiments. HUVECs
were treated with media containing angiotensin II (2 lM) for 18 h in
the presence or absence of globular adiponectin (2, 5, or 10 lg/ml,
Phoenix), sodium nitroprusside (SNP, an NO donor, 30 lM, Sigma),
NG-nitro-L-arginine methyl ether (L-NAME, an eNOS inhibitor, 100
lM, Sigma), radicicol (an HSP90 inhibitor, 20 lM, Calbiochem),
LY294002 (a phosphatidylinositol 3 ([PI3]) kinase inhibitor, 20 lM,
Sigma), losartan (an angiotensin II type I receptor blocker, 500 nM,
MSD) or PD123319 (an angiotensin II type II receptor blocker, 500
nM, Sigma).
2.2. Western blot
Cells were lysed in the lysis buﬀer (50 mMTris–HCl, 150 mMNaCl, 1
mM EGTA, 1% Nonidet P-40 [NP-40], 1 mM Na3VO4, 1 mM phen-
ylmethylsulfonylﬂuoride [PMSF], 1 mg/ml aprotinin, and leupeptin, pH
7.4) on ice for 20 min. The protein concentrations of the cell lysates
were determined. The cell lysates were subjected to electrophoresis on
8% sodium dodecyl sulfate–polyacrylamide gels (SDS–PAGE) for the
detection of eNOS, phospho-eNOS, Akt, and phospho-Akt. The
samples were then electrotransferred and immunoblotted with anti-
eNOS, anti-phospho-eNOS (Ser1177), anti-Akt or anti-phospho-Akt
(Ser473). After blocking, blots were incubated with horseradish per-
oxidase (HRP)-conjugated goat anti-mouse IgG (Cappel). The protein
expression was determined with the enhanced chemiluminescence
(ECL) kit (Amersham) and exposed to the ﬁlters of Kodak X-Omat
ﬁlms. b-actin was incorporated in the immunoblot as a control for the
loading protein amount.
2.3. Immunoprecipitation
Cell lysates were incubated with anti-eNOS polyclonal antibody
(StressGen) and protein A/G (Santa Cruz Biotechnology) to immu-
noprecipitate eNOS and then immunoblotted with anti-HSP90 anti-
body (StressGen) to determine the amount of HSP90 associated with
eNOS. Immunoglobulin G heavy chain was also immunoblotted as a
control for the loading protein amount.
2.4. Detection of apoptosis
Apoptosis of the treated HUVECs was detected by the ELISA
method of cell death detection (Roche Applied Science) and caspase-3
activation. This cell death detection assay is based on the quantitative
sandwich-enzyme-immunoassay principle using mouse monoclonal
antibodies directed against DNA and histones, respectively. It allows
speciﬁc determination of mono- and oligonucleosomes in the cell ly-
sates. Also, we determined the capase-3 activity by subjecting the cell
lysates to Western blotting with anti-caspase-3 polyclonal antibody
(Santa Cruz Biotech).
2.5. Statistical analysis
Data were expressed as meansS.E.M. Changes in apoptosis of
diﬀerent conditions were compared by unpaired Student’s t test when
the analysis of variance (ANOVA) showed signiﬁcant diﬀerence. A P
value <0.05 was considered statistically signiﬁcant.3. Results
3.1. Eﬀects of adiponectin on angiotensin II-induced apoptosis
in HUVECs
HUVECs were treated with angiotensin II (2 lM) for 18 h
with or without 1 h pre-treatment with globular adiponectin
(2, 5, or 10 lg/ml). Apoptosis was then measured. As shown
in Fig. 1A, angiotensin II-induced apoptosis was inhibited
by adiponectin in a dose–response manner. The caspase-3
cleavage product was present in the angiotensin II-treated
HUVECs, which was diminished by the pretreatment
with globular adiponectin in a dose–response manner
(Fig. 1B).3.2. The role of eNOS in the preventive eﬀect of adiponectin on
angiotensin II-induced apoptosis in HUVECs
As shown in Fig. 2A, angiotensin II-induced apoptosis in
HUVECs was inhibited by pre-treatment with globular
adiponectin (10 lg/ml), combined angiotensin II receptor
blockers (angiotensin II type I receptor blocker, Losartan, plus
angiotensin II type II receptor blocker, PD123319), or SNP for
1 h. Pre-treatment of HUVECs with L-NAME abolished the
anti-apoptotic eﬀect of adiponectin and combined angiotensin
II receptor blockers. Western blotting of caspase-3 (Fig. 2B)
showed that adiponectin and SNP could prevent the produc-
tion of caspase-3 cleavage product, while treatment with
L-NAME reversed this preventive eﬀect.
3.3. Eﬀect of adiponectin on the phosphorylation of eNOS and
Akt in angiotensin II-treated HUVECs
HUVECs were pre-treated with globular adiponectin or
combined angiotensin II blockers for 1 h followed by exposure
to angiotensin II for 18 h. The lysates of the treated cells were
then immunoblotted with anti-eNOS, anti-Akt, anti-phospho-
eNOS or anti-phospho-Akt antibody. As shown in Fig. 3, the
phosphorylation of eNOS and Akt was strongly expressed in
control experiment. eNOS phosphorylation was markedly in-
hibited by angiotensin II treatment and this eﬀect could be
prevented by pre-treatment of the cells with either globular
adiponectin or combined angiotensin II receptor blockers. The
expression of phospho-eNOS and phospho-Akt was similar in
cells treated with adiponectin and in control experiment.
LY294002, an inhibitor of PI3 kinase, could inhibit the phos-
phorylation of both Akt and eNOS. Of note, the protein
Fig. 2. Eﬀects of L-NAME (100 lM), combined angiotensin-II re-
ceptor blockers (Losartan, 500 nM and PD123319, 500 nM), and so-
dium nitroprusside (SNP, 30 lM) on angiotensin II-induced apoptosis
in HUVECs in the absence or presence of globular adiponectin (10 lg/
ml). (A) Angiotensin II-induced apoptosis in HUVECs is prevented by
globular adiponectin, combined angiotensin-II receptors blockers and
SNP, respectively. The preventive eﬀect of adiponectin and combined
angiotensin-II receptor blockers on angiotensin II-induced apoptosis is
blocked by L-NAME. (B) Lysates from treated HUVECs were im-
munoblotted with polyclonal antibody against caspase-3. The presence
of caspase-3 is prevented by treatment with globular adiponectin and
SNP, respectively. This preventive eﬀect is abolished by L-NAME.
Data are presented as means S.E.M. (n ¼ 3).
Fig. 3. The eﬀects of adiponectin and combined angiotensin II receptor
blockers on the expression and the phosphorylation of eNOS and Akt
in angiotensin-II treated HUVECs. HUVECs were exposed to angio-
tensin II for 18 h with or without pre-treatment with globular adipo-
nectin or combined angiotensin II receptor blockers (Losartan and
PD123319). Cell lysates were immunoblotted with anti-eNOS,
anti-Akt, anti-phospho-eNOS and anti-phospho-Akt polyclonal anti-
bodies. LY294002, a PI3 kinase inhibitor, could inhibit the phos-
phorylation of Akt and eNOS.
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cantly altered in all conditions.
3.4. Eﬀects of adiponectin on the association between eNOS and
HSP90
After pre-treatment with adiponectin or radicicol for 1 h,
HUVECs were subjected to angiotensin II exposure for 18 h.
The protein levels of eNOS, phospho-eNOS and HSP90 in the
cell lysates were measured. Proteins from the same cell lysates
were subjected to Western blotting and immunoprecipitation
for eNOS and HSP90. Our results showed that the association
between eNOS and HSP90 (Fig. 4A) and the phosphorylation
of eNOS (Fig. 4B) were signiﬁcantly inhibited by angioten-
sin II. Pre-treatment of the cells with globular adiponectin
could restore the eNOSnHSP90 association and the phos-
phorylation of eNOS while radicicol, an HSP90 inhibitor, re-
versed the eﬀects of adiponectin on eNOS and HSP90. Fig. 4CFig. 4. The eﬀects of adiponectin and radicicol on the association of
eNOSnHSP90 and the phosphorylation of eNOS in angiotensin-II
treated HUVECs. HUVECs were pre-treated with globular adipo-
nectin or radicicol before exposing to angiotensin II. (A) Lysates from
treated HUVECs were immunoprecipitated with polyclonal antibody
against eNOS. Immunoprecipitates were then Western blotted for
eNOS and HSP90. (B) Cell lysates were immunoblotted with anti-
phospho-eNOS and anti-eNOS polyclonal antibodies. (C) The pro-
tective eﬀect of adiponectin was abolished by radicicol. *, signiﬁcant
increase of apoptosis.
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giotensin II-induced apoptosis was abolished by pre-treatment
with radicicol.4. Discussion
In the present study, we demonstrated that globular adipo-
nectin can prevent angiotensin II-induced endothelial cell ap-
optosis through the promotion of the association between
eNOS and HSP90. Kobayashi et al. recently showed that the
high molecular weight form of adiponectin rather than trimer
or hexamer form could prevent HUVECs from apoptosis in-
duced by fasting [24]. The basic building block of adiponectin
is a tightly associated trimer, which is formed by association
between three monomers at the globular domains. Four to six
trimers associate through their collagenous domains to form
higher-order structures or oligomers. Without the collagenous
domain, the globular domain of adionectin still trimerizes but
does not associate into higher-order structures [26]. It is re-
vealed that diﬀerent recombinant adiponectin products might
produce diﬀerent pharmacological eﬀects. Studies on the bio-
activity of full length adiponectin comparing to that of the
globular domain alone have yielded divergent results [27,28]. It
is possible that adiponectin exists as variable protein com-
plexes that exert diﬀerent eﬀects in various tissues [26].
We showed that the phosphorylation of eNOS was strongly
upregulated at baseline in cells cultured in complete medium
(Fig. 3) and was markedly inhibited by LY294002, an inhib-
itor of the PI3 kinase-dependent-phosphorylation of Akt. This
indicated that the PI3 kinase-dependent phosphorylation of
Akt plays an important role in the phosphorylation of eNOS
in HUVECs. A number of studies have explored the intra-
cellular signaling pathways of endothelial cells that regulate
adiponectin-stimulated NO generation [9,10]. These studies
have pointed to a pivotal role of AMPK–PI3–kinase–Akt
dependent pathway in the phosphorylation of eNOS [9,10].
Yet, in the present study, we showed that Akt and phospho-
Akt strongly expressed at baseline and not changed through
the experiments (Fig. 3). There were several possible expla-
nations. First, in previous studies, endothelial cells were cul-
tured with serum-free or low serum medium for several hours
before putting the cells into experiment. This treatment would
markedly suppress the phosphorylation of Akt and eNOS as
compared with that in full medium (data not shown). In
contrast, in the present study, we used a medium containing
20% fetal calf serum in the experiments, which would induce a
prominent Akt phosphorylation and rendered a near satura-
tion for the phosphorylation of Akt at baseline. This would
make the eﬀect of adiponectin on Akt phosphorylation
masked. Second, we did not measure AMPK protein ex-
pression in this study. It is possible that eNOS was phos-
phorylated directly by AMPK [9,10]. But, this possibility
might be excluded from a recent study which showed that, in
HUVECs, AMPK functions upstream of Akt [10]. Of note,
eNOS can be phosphorylated on many residues. The phos-
phorylation of eNOS was detected by antibodies against
serine 1177, a most frequently studied phosphorylation site of
eNOS [10,13–15]. Whether there are other phosphorylated
residues of eNOS involved in the process needs further
investigation.The association between eNOS and HSP90 has recently been
demonstrated to be critical in the regulation of eNOS function
[13–17]. If not stimulated, eNOS is associated with caveolin
and remains in a membrane-bound, inactive state [29,30].
When stimulated with vascular endothelial growth factor
(VEGF), the eNOS–caveolin complex is disrupted by Ca(2+)/
calmodulin and the association between eNOS and HSP90 is
promoted [13]. The eNOS-bound HSP90 can then recruit
VEGF-activated Akt to the complex to induce phosphoryla-
tion of eNOS [13–15]. The binding of HSP90 to eNOS ensures
the transition from the early Ca2+-dependent to the late
phosphorylation-dependent activation of the eNOS [13].
Failure of this binding can cause eNOS uncoupling and in-
crease eNOS-dependent superoxide anion production [16]. One
of the novel ﬁndings of the present study is that angiotensin II
can inhibit the formation of eNOSnHSP90 complex through
an action on the angiotensin II receptor (Fig. 4A). In one in
vitro study, Marrero et al. [31] have demonstrated that an-
giotensin II receptor may directly bind eNOS to inhibit its
activity. Although the molecular pathway of angiotensin II
action is not completely clear, our results lead to the postu-
lation that stabilization of the eNOS/HSP90 complex pro-
duced by adiponectin could interfere with the binding to
angiotensin II receptor and prevent the angiotensin II-induced
de-activation of eNOS.
Angiotensin II importantly contributes to the pathobiology
of atherosclerosis and vascular disease not only via its role in
hypertension but also via its direct eﬀects on vascular cell in-
jury, growth and migration [21,32,33]. Studies on the eﬀect of
angiotensin II on apoptosis and NO production of endothelial
cells have revealed inconsistent results. Ohashi et al. [34]
showed that the apoptosis of porcine retinal endothelial cells
induced by serum starvation was inhibited by angiotensin II.
Cai et al. [35] showed that angiotensin II increased NO pro-
duction in bovine and mouse aortic endothelials cells. Bay-
raktutan [36,37] also showed that angiotensin II increased
eNOS activity and NO production in rat coronary and aortic
endothelials. One study has demonstrated that angiotensin II
can induce apoptosis of HUVECs via activation of the caspase
cascade and this eﬀect can be completely abrogated by NO
[21]. The study also showed that angiotensin II-induced ap-
optosis in HUVECs was aﬀected by the complex interplay
between type 1 and type 2 receptors of angiotensin II, as
demonstrated by a reduction in apoptosis when blockers of
both types of receptors were simultaneously added [21]. These
observations might imply that the eﬀects of angiotensin II on
the induction of apoptosis and NO production in endothelial
cells may be markedly aﬀected by the origin of the cells and
also the diﬀerence in species of experimental animals.
In this study, we showed that adiponectin can prevent det-
rimental eﬀect of angiotensin II by maintaining the stability of
eNOSnHSP90 complex. These observations have provided a
possible molecular mechanism for adiponectin in the protect-
ing eﬀects against vascular injury and remodeling [7,8]. Our
ﬁndings also proposed a new pathway for angiotensin–NO
interaction which holds an important impact on several car-
diovascular diseases [22].
In conclusion, we have delineated a possible signaling
pathway of adiponectin in preventing angiotensin II-induced
apoptosis in human endothelial cells. In this mechanism, eN-
OSnHSP90 uncoupling induced by angiotensin II is reversed
and the activation of caspase-3 and subsequent apoptosis is
110 L.-Y. Lin et al. / FEBS Letters 574 (2004) 106–110prohibited by the action of adiponectin. These ﬁndings may
contribute to the possible mechanism for adiponectin in direct
protection against vascular injury.References
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